{"nctId":"NCT03548987","briefTitle":"Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity","startDateStruct":{"date":"2018-06-04","type":"ACTUAL"},"conditions":["Metabolism and Nutrition Disorder","Obesity"],"count":902,"armGroups":[{"label":"Semaglutide","type":"EXPERIMENTAL","interventionNames":["Drug: Semaglutide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Semaglutide","Drug: Placebo"]}],"interventions":[{"name":"Semaglutide","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, age greater than or equal to 18 years at the time of signing informed consent\n* Body mass index greater than or equal to 30 kg/sqm or greater than or equal to 27 kg/sqm with the presence of at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease\n* History of at least one self-reported unsuccessful dietary effort to lose body weight\n\nExclusion Criteria:\n\n* Haemoglobin A1c greater than or equal to 48 mmol/mol (6.5%) as measured by central laboratory at screening\n* A self-reported change in body weight more than 5 kg (11 lbs) within 90 days before screening irrespective of medical records","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Randomisation to Week 68 in Body Weight (%)","description":"Change in body weight from baseline (week 20) to week 68 is presented. The endpoint was evaluated based on the data from both in-trial and on-treatment observation periods. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75). On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.3","spread":"8.1"},{"groupId":"OG001","value":"6.5","spread":"7.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.8","spread":"7.8"},{"groupId":"OG001","value":"6.1","spread":"7.7"}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference","description":"Change in waist circumference from baseline (week 20) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.9","spread":"7.5"},{"groupId":"OG001","value":"3.2","spread":"7.0"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure","description":"Change in systolic blood pressure from week 20 to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"14"},{"groupId":"OG001","value":"5","spread":"13"}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure","description":"Change in diastolic blood pressure from week 20 to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"9"},{"groupId":"OG001","value":"1","spread":"9"}]}]}]},{"type":"SECONDARY","title":"Change in Physical Functioning Score (Short Form 36 [SF-36])","description":"SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured eight domains of functional health and well-being as well as two component summary scores (physical component summary and mental component summary). The 0-100 scale scores from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. In the metric of norm-based scores, 50 and 10 corresponds to the mean and standard deviation respectively. Change from week 20 in the domain scores and component summary scores were evaluated at week 68. A positive change score indicates an improvement since baseline. These endpoints were evaluated based on the data from in-trial observation period which is the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"3.8"},{"groupId":"OG001","value":"-1.2","spread":"4.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"5.0"},{"groupId":"OG001","value":"-0.9","spread":"5.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"7.0"},{"groupId":"OG001","value":"-1.5","spread":"7.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"5.2"},{"groupId":"OG001","value":"-1.8","spread":"5.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"7.1"},{"groupId":"OG001","value":"-2.1","spread":"7.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"6.2"},{"groupId":"OG001","value":"-1.8","spread":"6.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"6.2"},{"groupId":"OG001","value":"-2.2","spread":"7.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"4.9"},{"groupId":"OG001","value":"-0.9","spread":"5.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"6.2"},{"groupId":"OG001","value":"-2.4","spread":"8.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"5.5"},{"groupId":"OG001","value":"-2.2","spread":"7.0"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight [Kilogram (Kg)]","description":"Change in body weight from week 20 to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.5","spread":"7.6"},{"groupId":"OG001","value":"5.7","spread":"6.7"}]}]}]},{"type":"SECONDARY","title":"Change in Body Mass Index (BMI)","description":"Change in BMI from week 20 to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"2.7"},{"groupId":"OG001","value":"2.0","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Change in Haemoglobin A1c (HbA1c) [%]","description":"Change in HbA1c from week 20 to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.3"},{"groupId":"OG001","value":"0.1","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c [Millimoles Per Mole (mmol/Mol)]","description":"Change in HbA1c from week 20 to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"2.8"},{"groupId":"OG001","value":"1.2","spread":"2.7"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose [Milligrams Per Deciliter (mg/dL)]","description":"Change in fasting plasma glucose from week 20 to week 68 is presented.The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"8.6"},{"groupId":"OG001","value":"7.6","spread":"10.0"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose [Millimoles Per Litre (mmol/L)]","description":"Change in fasting plasma glucose from week 20 to week 68 is presented.The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.5"},{"groupId":"OG001","value":"0.4","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Serum Insulin","description":"Change in fasting serum insulin from baseline (week 20) to week 68 \\[measured as milli-international units per milliliter (mIU/mL)\\] is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":"60.9"},{"groupId":"OG001","value":"1.03","spread":"64.6"}]}]}]},{"type":"SECONDARY","title":"Change in Total Cholesterol","description":"Change in fasting total cholesterol from baseline (week 20) to week 68 (measured as mmol/L) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":"13.5"},{"groupId":"OG001","value":"1.11","spread":"14.4"}]}]}]},{"type":"SECONDARY","title":"Change in High-density Lipoproteins (HDL)","description":"Change in fasting HDL from baseline (week 20) to week 68 (measured as mmol/L) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.18","spread":"13.2"},{"groupId":"OG001","value":"1.18","spread":"16.3"}]}]}]},{"type":"SECONDARY","title":"Change in Low-density Lipoproteins (LDL)","description":"Change in fasting LDL from baseline (week 20) to week 68 (measured as mmol/L) is presented as ratio to baseline.The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"19.8"},{"groupId":"OG001","value":"1.07","spread":"21.3"}]}]}]},{"type":"SECONDARY","title":"Change in Very Low-density Lipoproteins (VLDL)","description":"Change in fasting VLDL from baseline (week 20) to week 68 (measured as mmol/L) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","spread":"33.6"},{"groupId":"OG001","value":"1.12","spread":"39.0"}]}]}]},{"type":"SECONDARY","title":"Change in Free Fatty Acids","description":"Change in fasting free fatty acids from baseline (week 20) to week 68 (measured as mmol/L) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.78","spread":"79.4"},{"groupId":"OG001","value":"0.89","spread":"73.1"}]}]}]},{"type":"SECONDARY","title":"Change in Triglycerides","description":"Change in fasting triglycerides from baseline (week 20) to week 68 (measured as mmol/L) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","spread":"33.9"},{"groupId":"OG001","value":"1.12","spread":"39.4"}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieve (Yes/no): Responder Definition Value for SF-36 Physical Functioning Score","description":"The number of participants achieving at least a 4.3-point increase in SF-36 physical functioning score from baseline (week 20) to week 68 is presented. In the reported data, 'Yes' infers number of participants who have achieved 4.3 points of increase of the score and 'No' infers number of participants who have not achieved 4.3 points of increase of the score. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"457","spread":null},{"groupId":"OG001","value":"234","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects Who Gain Weight (Yes/no)","description":"The number of participants with weight gain from the start of the randomised period (week 20) to week 68 is presented. In the reported data, 'Yes' infers number of participants who have gained weight and 'No' infers number of participants who have not gained weight. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"206","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"441","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":"The body weight change (%) from week 0 to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.7","spread":"9.8"},{"groupId":"OG001","value":"-5.4","spread":"7.3"}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieve (Yes/no): Body Weight Reduction < 0%","description":"The number of participants who achieved less than (\\<) 0% weight loss from week 0 to week 68 is presented. In the reported data, 'Yes' infers number of participants who have achieved \\<0% weight loss whereas 'No' infers number of participants who have not achieved \\<0% weight loss.The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"498","spread":null},{"groupId":"OG001","value":"199","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieve (Yes/no): Body Weight Reduction ≥ 5%","description":"The number of participants who achieved greater than or equal to (≥) 5% weight loss from week 0 to week 68 is presented. In the reported data, 'Yes' infers number of participants who have achieved ≥ 5% weight loss whereas 'No' infers number of participants who have not achieved ≥ 5% weight loss. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"461","spread":null},{"groupId":"OG001","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"131","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieve (Yes/no): Body Weight Reduction ≥ 10%","description":"The number of participants who achieved ≥ 10% weight loss from week 0 to week 68 is presented. In the reported data, 'Yes' infers number of participants who have achieved ≥ 10% weight loss whereas 'No' infers number of participants who have not achieved ≥ 10% weight loss. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"411","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"199","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieve (Yes/no): Body Weight Reduction ≥ 15%","description":"The number of participants who achieved ≥ 15% weight loss from week 0 to week 68 is presented. In the reported data, 'Yes' infers number of participants who have achieved ≥ 15% weight loss whereas 'No' infers number of participants who have not achieved ≥ 15% weight loss. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of run-in (week 0) to last trial-related subject-site contact (week 75).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"331","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":null},{"groupId":"OG001","value":"227","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment-emergent Adverse Events (AEs)","description":"An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. All AEs mentioned here are treatment emergent adverse events (TEAE) defined as an event that had onset date (or increase in severity) on or after the first day of exposure to treatment (week 0-20 run-in period). The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68), including 7 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 7 consecutive missed doses (off-treatment period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3775","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment-emergent AEs","description":"An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. All AEs mentioned here are TEAE defined as an event that had onset date (or increase in severity) on or after the first day of exposure to treatment (week 20-75). The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68), including 7 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 7 consecutive missed doses (off-treatment period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1885","spread":null},{"groupId":"OG001","value":"779","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Serious Adverse Events (SAEs)","description":"A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. The SAEs occurred during run-in period from week 0 to week 20 is presented. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68), including 7 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 7 consecutive missed doses (off-treatment period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Serious Adverse Events (SAEs)","description":"A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. The SAEs occurred during run-in period from week 0 to week 20 is presented. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68), including 7 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 7 consecutive missed doses (off-treatment period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Pulse","description":"Change in pulse rate from week 0 week to week 20 is presented. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"9"},{"groupId":"OG001","value":"5","spread":"9"}]}]}]},{"type":"SECONDARY","title":"Change in Pulse","description":"Change in pulse from week 20 and 68 is presented. The endpoint was evaluated based on the data from on-treatment observation period.On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2","spread":"9"},{"groupId":"OG001","value":"-5","spread":"10"}]}]}]},{"type":"SECONDARY","title":"Change in Amylase","description":"Change in amylase (measured as units per liter \\[U/L\\]) is presented as ratio to baseline. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.06","spread":"18.7"},{"groupId":"OG001","value":"1.02","spread":"26.2"}]}]}]},{"type":"SECONDARY","title":"Change in Amylase","description":"Change in amylase (measured as U/L) is presented as ratio to baseline. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.06","spread":"19.9"},{"groupId":"OG001","value":"1.00","spread":"24.9"}]}]}]},{"type":"SECONDARY","title":"Change in Lipase","description":"Change in lipase (measured as U/L) is presented as ratio to baseline. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.44","spread":"40.2"},{"groupId":"OG001","value":"1.39","spread":"53.5"}]}]}]},{"type":"SECONDARY","title":"Change in Lipase","description":"Change in lipase (measured as U/L) is presented as ratio to baseline. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","spread":"37.8"},{"groupId":"OG001","value":"0.68","spread":"51.7"}]}]}]},{"type":"SECONDARY","title":"Change in Calcitonin","description":"Change in calcitonin (measured as nanogram per liter (ng/L)\\]) is presented as ratio to baseline. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"28.4"},{"groupId":"OG001","value":"0.96","spread":"28.1"}]}]}]},{"type":"SECONDARY","title":"Change in Calcitonin","description":"Change in calcitonin (measured as ng/L) is presented as ratio to baseline. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"24.8"},{"groupId":"OG001","value":"0.95","spread":"25.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":902},"commonTop":["Nausea","Diarrhoea","Constipation","Vomiting","Nasopharyngitis"]}}}